Royalty Pharma plc (RPRX) stock
RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3050% above fair value
$68.68+0.16 (+0.23%)
Close on Nov 17, 2026Market cap $39.49BP/E 39.0Yield –
Royalty Pharma price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Royalty Pharma's price to sales ratio was 15.4× on Nov 11, 2026, against 9.7× a year earlier. Over the last 5 years it ranged from 6.4× to 15.4×, with a median of 8.8×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 15.4× | +6.0 |
| 2025 | Dec 31, 2025 | 9.4× | +2.7 |
| 2024 | Dec 31, 2024 | 6.7× | −0.1 |
| 2023 | Dec 29, 2023 | 6.8× | −3.1 |
| 2022 | Dec 30, 2022 | 9.9× | +0.2 |
| 2021 | Dec 31, 2021 | 9.7× | – |
See a number that looks wrong?